Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 14c
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Join SI Premium – FREE
Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.78), $0.14 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $35 million versus the consensus estimate of $33.65 million.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citizens launches transportation coverage, names FedEx a top large-cap pick
- SemiLEDS (LEDS) Tops Q3 EPS by 18c
- Surge Components, Inc. (SPRS) Tops Q2 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
The Children's Investment Fund (TCI), EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
